{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:10:22Z","timestamp":1789596622961,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.diabet.2019.12.007","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T09:04:40Z","timestamp":1578387880000},"page":"427-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-6329","authenticated-orcid":false,"given":"A.","family":"Mantovani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Scorletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"G.","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2019.12.007_bib0265","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.diabet.2019.12.007_bib0270","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0275","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0280","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2019.12.007_bib0285","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2019.12.007_bib0290","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL)","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0295","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1080\/14656566.2018.1531126","article-title":"Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease","volume":"19","author":"Raschi","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabet.2019.12.007_bib0300","doi-asserted-by":"crossref","DOI":"10.3390\/diseases6040093","article-title":"Anti-diabetic medications for the pharmacologic management of NAFLD","volume":"6","author":"Cholankeril","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.diabet.2019.12.007_bib0305","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2288-12-140","article-title":"Methods for the drug effectiveness review project","volume":"12","author":"McDonagh","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0749-3797(01)00261-6","article-title":"Current methods of the US Preventive Services Task Force: a review of the process","volume":"20","author":"Harris","year":"2001","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.diabet.2019.12.007_bib0315","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0320","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0325","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MEG.0b013e32832e2baf","article-title":"Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease","volume":"22","author":"Omer","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0330","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2019.12.007_bib0335","doi-asserted-by":"crossref","first-page":"e9270","DOI":"10.5812\/hepatmon.9270","article-title":"The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic fatty liver disease: a randomized double blinded clinical trial","volume":"13","author":"Razavizade","year":"2013","journal-title":"Hepat Mon"},{"key":"10.1016\/j.diabet.2019.12.007_bib0340","article-title":"Comparative effect of insulin sensitizers and statin on metabolic profile and ultrasonographical score in non-alcoholic fatty liver disease","volume":"10","author":"Rana","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.diabet.2019.12.007_bib0345","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2019.12.007_bib0350","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2019.12.007_bib0355","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2019.12.007_bib0360","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2019.12.007_bib0365","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.24558","article-title":"Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial","volume":"54","author":"Torres","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2019.12.007_bib0370","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jceh.2012.10.010","article-title":"A randomized controlled trial comparing efficacy of pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis","volume":"2","author":"Sharma","year":"2012","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0375","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2019.12.007_bib0380","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/dmrr.2561","article-title":"Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes","volume":"30","author":"Shao","year":"2014","journal-title":"Diab Metab Res Rev"},{"key":"10.1016\/j.diabet.2019.12.007_bib0385","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2019.12.007_bib0390","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2019.12.007_bib0395","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1753-0407.12555","article-title":"Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease","volume":"9","author":"Feng","year":"2017","journal-title":"J Diab"},{"key":"10.1016\/j.diabet.2019.12.007_bib0400","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.13053","article-title":"Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial","volume":"20","author":"Fr\u00f8ssing","year":"2018","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2019.12.007_bib0405","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2019.12.007_bib0410","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2014-3794","article-title":"Effect of vildagliptin on hepatic steatosis","volume":"100","author":"Macauley","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2019.12.007_bib0415","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0420","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/MEG.0000000000000780","article-title":"Short article: a randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease","volume":"29","author":"Deng","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0425","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2019.12.007_bib0430","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2019.12.007_bib0435","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","author":"Cusi","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2019.12.007_bib0440","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2019.12.007_bib0445","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2019.12.007_bib0450","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2019.12.007_bib0455","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","author":"Kahl","year":"2019","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2019.12.007_bib0460","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/hep.30672","article-title":"Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum","volume":"70","author":"Cheung","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2019.12.007_bib0465","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2017.12.001","article-title":"A critical review of endpoints for non-cirrhotic NASH therapeutic trials","volume":"68","author":"Ratziu","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0470","first-page":"252","article-title":"End-points for drug treatment in NASH","volume":"13","author":"Adams","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.diabet.2019.12.007_bib0475","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes \u2013 2018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2019.12.007_bib0480","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabet.2019.12.007_bib0485","article-title":"Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance","volume":"354","author":"Glen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2019.12.007_bib0490","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2019.12.007_bib0495","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2019.12.007_bib0500","article-title":"Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus: new kids on the block","author":"Athyros","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0505","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diab Endocrinol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0510","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2019.12.007_bib0515","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-019-0903-4","article-title":"Class effects of SGLT2 inhibitors on cardiorenal outcomes","volume":"18","author":"Kluger","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2019.12.007_bib0520","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363620300021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363620300021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:56:38Z","timestamp":1761130598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363620300021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1262363620300021"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2019.12.007","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2019.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}